滚动资讯
Endpoints NewsDid Eli Lilly just strike another gold mine?Endpoints NewsWhat’s familiar in health tech’s Q1 funding totalsEndpoints NewsStudy suggests $35 monthly insulin cap has increased patient accessPromega BlogNew Study Suggests Cancer Research Has an Age ProblemEndpoints NewsWhite House adds AbbVie's Humira to TrumpRx alongside cheaper biosimilarsBioPharma DiveTerns rebuffed a higher bid before selling to MerckFierceBiotechLilly pays AC Immune $12.5M to expand Alzheimer’s collab as asset draws closer to clinicFierceBiotechLongtime Hologic CEO Steve MacMillan to retire as $18.3B deal closesFierceBiotechOwlet CEO exits suddenly, co-founder returns to the nestFierceBiotechE2 lands $80M series C for next gen thrombectomy treatmentFierceBiotechCRO Fortrea launches AI-powered solution to improve trial efficiencyBioWorldAppointments and advancements for April 7, 2026
Cytiva (Google News) 2026年2月19日

2030年细胞与基因治疗工具及试剂市场展望:规模达198亿美元,赛默飞世尔、思拓凡(丹纳赫)、默克、美天旎、赛多利斯等企业领衔——雅虎财经

2030年细胞与基因治疗工具及试剂市场展望:规模达198亿美元,赛默飞世尔、思拓凡(丹纳赫)、默克、美天旎、赛多利斯等企业领衔——雅虎财经

暂时没有全文,请查看原始来源。

目录

59 全部